Aimmune BLA submission right on time, says Piper Jaffray

Piper Jaffray analyst Christopher Raymond kept an Overweight rating and $60 price target on Aimmune Therapeutics following the AR101 BLA submission for peanut allergy in children and adolescents ages 4-17. The analyst said he expects “this BLA will not only be accepted but may also receive Priority Review, putting it on track for a late summer approval/launch” and believes “the FDA will like this one.” Raymond continues to “view the set-up on this name as decidedly positive” and remains a buyer of Aimmune shares.
https://thefly.com/landingPageNews.php?id=2840879